Tori Marsh - August 16, 2018
Have you ever gone to the pharmacy only to realize that you’re on the hook for a high copay or your insurance just won’t cover your medication at all. You’re not alone. Luckily, many drug manufacturers offer savings through copay cards, also known as manufacturer coupons. These programs are typically for brand-name drugs, and can lower the price of your medication to as little as $0.
GoodRx currently has information on over 680 active copay cards for hundreds of prescription medications. See More
Tori Marsh - July 26, 2018
Brand-only drugs like Restasis, Eliquis and Lyrica can cost well over $500 for a month’s supply, and without cheaper generic alternatives, patients are often forced to either shell out their life savings or give up essential medications. FDA initiatives to expedite the drug review process and prohibit manufacturers from holding market exclusivity for too long will hopefully bring many generics to the market soon. See More
Dr. Sharon Orrange - July 16, 2018
Trulicity, Victoza, and Bydureon all belong to a newer class of non-insulin diabetes medications known as GLP-1 (glucagon-like peptide-1) receptor agonists that improve blood sugar control and may lead to weight loss. They were each approved by the FDA in the last decade, and increase how much insulin the pancreas makes in response to high glucose levels.
Which drug is the most effective?
Trulicity (dulaglutide), approved in 2014, is the newest out of these three drugs. See More
Tori Marsh - June 27, 2018
Let’s start with the bad news. Invokana, a tablet taken to treat type 2 diabetes, is really expensive. A 30-day supply of Invokana can cost around $550, and we may have to wait another six years to see a generic. But there is good news — there are ways to save.
Here’s all the information you need to make your Invokana prescription affordable.
How popular is Invokana?
Approved in 2013, Invokana is one of the most popular SGLT2 inhibitors, a class of drugs that is used to treat diabetes type 2 by blocking the kidneys from reabsorbing glucose so any excess is excreted from the body. See More
Tori Marsh - June 14, 2018
Brand drugs are expensive — this we already know, and prices seem to only be increasing. Of the 100 most-prescribed brand-name medications, those for diabetes, rheumatoid arthritis, and Crohn’s disease tend to be the most expensive. All of the drugs on this list are brand-only medications, meaning that there are no affordable generic alternatives available.
Additionally, it can be difficult for people to receive adequate insurance coverage for many of these drugs as they may be placed in more expensive, higher-tier formularies or have some other coverage restrictions. See More
Tori Marsh - February 08, 2018
Between the supplies, the physician visits, and the prescription medications, treating diabetes can be expensive. In fact, the average patient spends an average of $7,900 per year to treat their diabetes. Doctors consistently report that the high costs for diabetes medications can result in low levels of adherence, so it is important for patients to find ways to save.
Roni Shye - January 16, 2018
If you’ve ever been afraid to show up at your doctor’s office because you’ve been “bad” then this post is for YOU! You may think your doctor is “pushing medications on you” especially if you aren’t experiencing any symptoms of the condition they are treating you for. However, their reasoning is not without sound medical and professional judgment.
One of the many reasons you might receive a lecture about the importance of taking your medications is due to the progressive nature of many diseases if not properly treated. See More
Dr. Sharon Orrange - October 06, 2015
More than 29 million Americans have diabetes. That’s more than 10% of the US—and that number continues to rise. More than 1.7 million adults were diagnosed with diabetes in 2012 alone.
Fortunately, several new medications for diabetes have recently been approved—Toujeo (a new insulin product), Synjardy (a new combination of empagliflozin/metformin) and others. These new drugs provide several benefits such as fewer side effects or foolproof self-dosing with an insulin pen. See More
Roni Shye - September 04, 2015
On August 28, 2015, the FDA issued a safety warning for a newer type of type 2 diabetes medication known as DPP-4 inhibitors or gliptins.
There have been reports that these medications can cause severe and possibly disabling joint pain.
Which medications contain gliptins (DPP-4 inhibitors)?
- Januvia (sitagliptin)
- Onglyza (saxagliptin)
- Tradjenta (linagliptin)
- Nesina (alogliptin)
- Janumet and Janumet XR (metformin and sitagliptin)
- Kombiglyze XR (saxagliptin and metformin)
- Glyxambi (empagliflozin and linagliptin)
- Jentadueto (metformin and linagliptin)
- Kazano (alogliptin and metformin)
- Oseni (alogliptin and pioglitazone)
Why was a FDA safety warning issued for gliptin medications?
The FDA issued the warning due to continued reports of severe joint pain associated with the use of gliptin medications. See More
Dr. Sharon Orrange - January 02, 2014
2013 was a year for many new treatments for type II diabetes. For healthcare workers and patients it’s hard to keep up with the newer medications for the treatment of adult onset diabetes, and treating diabetes is an art and not a “one-size fits all” algorithm. For our folks struggling with type II diabetes the outlook just got brighter because of a class of drugs known as incretin based drugs. Here is the down-low on these medications. See More